Previous 10 | Next 10 |
BOSTON, March 09, 2023 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company and world leader in galectin biology focused on the development of novel treatments for fibrosis and cancer, today announced its operating and financial results for the quarter and year...
BOSTON, March 02, 2023 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company and a world leader in galectin biology focused on the development of novel treatments for fibrosis and cancer, today announced that management will present and be available for 1x1 meet...
BOSTON, Feb. 01, 2023 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company and a world leader in galectin biology focused on the development of novel treatments for fibrosis and cancer, today announced that management will present at the upcoming SVB Securities...
Intermediate assessment of GB2064 in the Phase 2 myelofibrosis trial showed target engagement in the bone marrow and reduction in collagen fibrosis in four out of five evaluable patients GB2064 is an oral inhibitor of the collagen cross-linking enzyme LOXL-2, which is linked to myelofibro...
Galecto press release ( NASDAQ: GLTO ): Q3 GAAP EPS of -$0.54. Cash, cash equivalents, and investments as of September 30, 2022 were approximately $75.9 million. The Company anticipates that its cash, cash equivalents and investments will be sufficient to fund operating ex...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: f11photo/Shutterstock.com We’re starting off the day with a look at the biggest pre-market stock movers traders need to know about on Tuesday! Moving stocks this morning are earnings reports, stock of...
Galecto ( NASDAQ: GLTO ) said its medicine GB1211 helped reduce certain liver enzymes in patients with decompensated cirrhosis in a phase 1b/2a trial. The study, dubbed GULLIVER-2, evaluated GB1211 in up to 54 participants, which included patients with decompen...
Statistically significant reductions observed in ALT, AST and GGT, supporting further development of GB1211 in severe liver diseases Findings to be discussed in a conference call and virtual webinar today, November 8, 2022, at 8 a.m. ET BOSTON, Nov. 08, 2022 (GLOB...
BOSTON, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company and a world leader in galectin biology focused on the development of novel treatments for fibrosis and cancer, today announced that management will present at the upcoming Jefferie...
Late-breaking oral and poster presentations include clinical and preclinical data related to GULLIVER-2 clinical trial Galecto to host a webinar at 8:00 a.m. ET on Tuesday, November 8, 2022 to discuss expanded topline data and analysis BOSTON, Oct. 31, 2022 (GLOBE NEWSWI...
News, Short Squeeze, Breakout and More Instantly...
BOSTON, May 01, 2024 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for cancer and fibrosis, today announced that the first patient has been enrolled in an investigator-initiated Phase 2 trial to evaluate GB1...
Morgan Advanced Materials Plc (MCRUF) is expected to report for Q4 2023 Security Federal Corp (SFDL) is expected to report for Q1 2024 Bank of the James Financial Group Inc. (BOTJ) is expected to report for Q1 2024 OMV AG (OMVJF) is expected to report $1.91 for Q1 2024 Pola Orbis ...